Nurix Therapeutics (NRIX) Enterprise Value (2020 - 2026)

Nurix Therapeutics (NRIX) has reported Enterprise Value for 8 consecutive years, with -$443.5 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Enterprise Value rose 8.7% year-over-year to -$443.5 million; the TTM figure through May 2026 stood at -$443.5 million (up 8.7% YoY), while the FY2025 annual figure was -$592.9 million, up 2.73% from the prior year.
• Enterprise Value advanced to -$443.5 million in Q2 2026 per NRIX's latest filing, from -$540.7 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$244.0 million in Q1 2024 and bottomed at -$609.6 million in Q4 2024.
• Historically, Enterprise Value has averaged -$394.7 million across 5 years, with a median of -$386.7 million in 2022.
• Annual changes were most pronounced in 2023 — Enterprise Value gained 24.86% — and 2025, when it sank 125.29%.
• Nurix Therapeutics' Enterprise Value stood at -$309.1 million in 2022, then climbed by 6.87% to -$287.9 million in 2023, then plunged by 111.73% to -$609.6 million in 2024, then grew by 2.73% to -$592.9 million in 2025, then climbed by 25.2% to -$443.5 million in 2026.
• Business Quant data shows NRIX's Enterprise Value at -$443.5 million in Q2 2026, -$540.7 million in Q1 2026, and -$592.9 million in Q4 2025.